In this episode, we're joined by Louisa Oliver Byrne, Senior Consultant at Access Infinity. We learn about the complexities of the Most Favored Nation (MFN) policy and its implications for pharmaceutical market access. Louisa shares insights from her recent research on MFN, exploring how direct-to-consumer pricing models might actually play out in practice, and why the policy's stated goals don't always align with likely outcomes. From "brown bagging" concerns to payer behaviour shifts, this ...
All content for Market Access Matters is the property of Access Infinity and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In this episode, we're joined by Louisa Oliver Byrne, Senior Consultant at Access Infinity. We learn about the complexities of the Most Favored Nation (MFN) policy and its implications for pharmaceutical market access. Louisa shares insights from her recent research on MFN, exploring how direct-to-consumer pricing models might actually play out in practice, and why the policy's stated goals don't always align with likely outcomes. From "brown bagging" concerns to payer behaviour shifts, this ...
Yvonne Hilsky, Moderna, on why it's important to understand the building blocks of market access.
Market Access Matters
19 minutes
1 year ago
Yvonne Hilsky, Moderna, on why it's important to understand the building blocks of market access.
In this episode we're joined by Yvonne Hilsky who is Director of Market Access at Moderna. Having spent over 30 years in industry, Yvonne shares her views on what it takes to be successful in market access, including why making mistakes are an opportunity for growth. Yvonne explores why it's important to have strong foundations and understand the 'building blocks' of market access and shares great stories from the early stages of her career, which we're sure will resonate with ma...
Market Access Matters
In this episode, we're joined by Louisa Oliver Byrne, Senior Consultant at Access Infinity. We learn about the complexities of the Most Favored Nation (MFN) policy and its implications for pharmaceutical market access. Louisa shares insights from her recent research on MFN, exploring how direct-to-consumer pricing models might actually play out in practice, and why the policy's stated goals don't always align with likely outcomes. From "brown bagging" concerns to payer behaviour shifts, this ...
